202 related articles for article (PubMed ID: 31662324)
21. Dual PI3K/mTOR inhibitor PKI-402 suppresses the growth of ovarian cancer cells by degradation of Mcl-1 through autophagy.
Hu X; Xia M; Wang J; Yu H; Chai J; Zhang Z; Sun Y; Su J; Sun L
Biomed Pharmacother; 2020 Sep; 129():110397. PubMed ID: 32585451
[TBL] [Abstract][Full Text] [Related]
22. Role of Ku70 in deubiquitination of Mcl-1 and suppression of apoptosis.
Wang B; Xie M; Li R; Owonikoko TK; Ramalingam SS; Khuri FR; Curran WJ; Wang Y; Deng X
Cell Death Differ; 2014 Jul; 21(7):1160-9. PubMed ID: 24769731
[TBL] [Abstract][Full Text] [Related]
23. Deactivation of Akt by a small molecule inhibitor targeting pleckstrin homology domain and facilitating Akt ubiquitination.
Jo H; Lo PK; Li Y; Loison F; Green S; Wang J; Silberstein LE; Ye K; Chen H; Luo HR
Proc Natl Acad Sci U S A; 2011 Apr; 108(16):6486-91. PubMed ID: 21464312
[TBL] [Abstract][Full Text] [Related]
24. Apigenin sensitizes colon cancer cells to antitumor activity of ABT-263.
Shao H; Jing K; Mahmoud E; Huang H; Fang X; Yu C
Mol Cancer Ther; 2013 Dec; 12(12):2640-50. PubMed ID: 24126433
[TBL] [Abstract][Full Text] [Related]
25. YES1 Drives Lung Cancer Growth and Progression and Predicts Sensitivity to Dasatinib.
Garmendia I; Pajares MJ; Hermida-Prado F; Ajona D; Bértolo C; Sainz C; Lavín A; Remírez AB; Valencia K; Moreno H; Ferrer I; Behrens C; Cuadrado M; Paz-Ares L; Bustelo XR; Gil-Bazo I; Alameda D; Lecanda F; Calvo A; Felip E; Sánchez-Céspedes M; Wistuba II; Granda-Diaz R; Rodrigo JP; García-Pedrero JM; Pio R; Montuenga LM; Agorreta J
Am J Respir Crit Care Med; 2019 Oct; 200(7):888-899. PubMed ID: 31166114
[No Abstract] [Full Text] [Related]
26. Overexpression of Antiapoptotic MCL-1 Predicts Worse Overall Survival of Patients With Non-small Cell Lung Cancer.
Nakano T; Go T; Nakashima N; Liu D; Yokomise H
Anticancer Res; 2020 Feb; 40(2):1007-1014. PubMed ID: 32014946
[TBL] [Abstract][Full Text] [Related]
27. Atorvastatin overcomes gefitinib resistance in KRAS mutant human non-small cell lung carcinoma cells.
Chen J; Bi H; Hou J; Zhang X; Zhang C; Yue L; Wen X; Liu D; Shi H; Yuan J; Liu J; Liu B
Cell Death Dis; 2013 Sep; 4(9):e814. PubMed ID: 24071646
[TBL] [Abstract][Full Text] [Related]
28. MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo.
Hirai H; Sootome H; Nakatsuru Y; Miyama K; Taguchi S; Tsujioka K; Ueno Y; Hatch H; Majumder PK; Pan BS; Kotani H
Mol Cancer Ther; 2010 Jul; 9(7):1956-67. PubMed ID: 20571069
[TBL] [Abstract][Full Text] [Related]
29. Akt inhibitor SC66 promotes cell sensitivity to cisplatin in chemoresistant ovarian cancer cells through inhibition of COL11A1 expression.
Wu YH; Huang YF; Chen CC; Chou CY
Cell Death Dis; 2019 Apr; 10(4):322. PubMed ID: 30975980
[TBL] [Abstract][Full Text] [Related]
30. Akt-mediated eminent expression of c-FLIP and Mcl-1 confers acquired resistance to TRAIL-induced cytotoxicity to lung cancer cells.
Wang X; Chen W; Zeng W; Bai L; Tesfaigzi Y; Belinsky SA; Lin Y
Mol Cancer Ther; 2008 May; 7(5):1156-63. PubMed ID: 18483303
[TBL] [Abstract][Full Text] [Related]
31. A sesquiterpene lactone antrocin from Antrodia camphorata negatively modulates JAK2/STAT3 signaling via microRNA let-7c and induces apoptosis in lung cancer cells.
Yeh CT; Huang WC; Rao YK; Ye M; Lee WH; Wang LS; Tzeng DT; Wu CH; Shieh YS; Huang CY; Chen YJ; Hsiao M; Wu AT; Yang Z; Tzeng YM
Carcinogenesis; 2013 Dec; 34(12):2918-28. PubMed ID: 23880305
[TBL] [Abstract][Full Text] [Related]
32. DYRK1A suppression restrains Mcl-1 expression and sensitizes NSCLC cells to Bcl-2 inhibitors.
Li Y; Zhou D; Xu S; Rao M; Zhang Z; Wu L; Zhang C; Lin N
Cancer Biol Med; 2020 May; 17(2):387-400. PubMed ID: 32587776
[No Abstract] [Full Text] [Related]
33. A small molecule inhibits Akt through direct binding to Akt and preventing Akt membrane translocation.
Kim D; Sun M; He L; Zhou QH; Chen J; Sun XM; Bepler G; Sebti SM; Cheng JQ
J Biol Chem; 2010 Mar; 285(11):8383-94. PubMed ID: 20068047
[TBL] [Abstract][Full Text] [Related]
34. A novel small-molecule PI3K/Akt signaling inhibitor, W934, exhibits potent antitumor efficacy in A549 non-small-cell lung cancer.
Wang J; Wang HY; Shen Y; Liang D; Wang HY; Zhang SQ; Cao YX; Cao L
Anticancer Drugs; 2019 Oct; 30(9):900-908. PubMed ID: 30913062
[TBL] [Abstract][Full Text] [Related]
35. Knockdown of CABYR-a/b increases chemosensitivity of human non-small cell lung cancer cells through inactivation of Akt.
Qian Z; Li M; Wang R; Xiao Q; Wang J; Li M; He D; Xiao X
Mol Cancer Res; 2014 Mar; 12(3):335-47. PubMed ID: 24362251
[TBL] [Abstract][Full Text] [Related]
36. Regulation of AKT Activity by Inhibition of the Pleckstrin Homology Domain-PtdIns(3,4,5)P
Kang Y; Jang G; Ahn S; Lee Y; Shim SY; Yoon Y
J Microbiol Biotechnol; 2018 Aug; 28(8):1401-1411. PubMed ID: 30301316
[TBL] [Abstract][Full Text] [Related]
37. Atorvastatin sensitizes human non-small cell lung carcinomas to carboplatin via suppression of AKT activation and upregulation of TIMP-1.
Chen J; Lan T; Hou J; Zhang J; An Y; Tie L; Pan Y; Liu J; Li X
Int J Biochem Cell Biol; 2012 May; 44(5):759-69. PubMed ID: 22305890
[TBL] [Abstract][Full Text] [Related]
38. Safflower polysaccharide induces NSCLC cell apoptosis by inhibition of the Akt pathway.
Li JY; Yu J; Du XS; Zhang HM; Wang B; Guo H; Bai J; Wang JH; Liu A; Wang YL
Oncol Rep; 2016 Jul; 36(1):147-54. PubMed ID: 27177149
[TBL] [Abstract][Full Text] [Related]
39. EGFR mutations and AKT phosphorylation are markers for sensitivity to combined MCL-1 and BCL-2/xL inhibition in non-small cell lung cancer.
Rice SJ; Liu X; Wang HG; Belani CP
PLoS One; 2019; 14(5):e0217657. PubMed ID: 31150457
[TBL] [Abstract][Full Text] [Related]
40. Delphinidin reduces cell proliferation and induces apoptosis of non-small-cell lung cancer cells by targeting EGFR/VEGFR2 signaling pathways.
Pal HC; Sharma S; Strickland LR; Agarwal J; Athar M; Elmets CA; Afaq F
PLoS One; 2013; 8(10):e77270. PubMed ID: 24124611
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]